CoChat

Dose response of continuous subcutaneous infusion of recombinant glucagon‐like peptide‐1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus

Torekov, S. S., Holst, J. J., Ehlers, M. R. · 2014 · Diabetes, Obesity and Metabolism
Cited by 14

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims: Any differences observed between natural glucagon‐like peptide‐1 (GLP‐1) and studies obtained with analogues might call for renewed considerations concerning the use and design of such analogues. Thus, we aimed to evaluate the dose–response relationship of recombinant glucagon‐like peptide‐1 (7–36) amide (rGLP‐1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes. Methods: We compared the efficacy and safety of three doses of recombinant GLP‐1, ranging from 1.25 to 5.0 pmol/kg/min (pkm) and placebo, given by continuous subcutaneous infusion over 3 months in combination with metformin and sulphonylurea (SU), to lower haemoglobin A1c (HbA1c), fasting plasma glucose and weight in 95 type 2 diabetes patients with inadequate glycaemic control. Results: The mean decreases in HbA1c at endpoint (week 12) were significantly greater for all three rGLP‐1 dose groups when each was compared with the placebo group, with the greatest decrease occurring in the 5.0 pkm dose group (−1.3%, s.d. ± 0.18, p < 0.001). The mean decreases in fasting plasma glucose from baseline to endpoint were significantly greater for all three rGLP‐1 dose groups than for the placebo group, with the greatest decrease occurring in the 5.0 pkm dose group (−26.0 mg/dl, s.d. ± 8.5, p = 0.02). Body weight was significantly reduced by 1.8 kg (s.d. ± 1.3) in the 1.25 pkm dose group only (p = 0.04). Conclusions: Administration of rGLP‐1 by CSCI over a 12‐week period in combination with metformin and an SU had a dose dependent effect in lowering HbA1c and fasting plasma glucose. However, administration of rGLP‐1 by CSCI may be less effective with respect to lowering of body weight compared with the daily and once weekly analogues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12240

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 14

Metadata

Authors
Torekov, S. S., Holst, J. J., & Ehlers, M. R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-12-10
Volume
16
Issue
5
Pages
451-456
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2034062059
Cited by
14
References
6
FWCI
1.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.